These Cholesterol-Reducers May Save Lives. So Why Aren’t Heart Patients Getting Them?

Powerful PCSK9 inhibitors were supposed to revolutionize care for cardiac patients. But insurers and other payers balked at sky-high prices.

from NYT > Health https://ift.tt/2DOXLNk
via health&fitness